Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
The present invention relates to the use of PDGF receptor tyrosine kinase inhibitors, especially of N-phenyl-2-pyrim-idine-amine derivatives of formula (I), in which the symbols and substituents have the meaning as defined herein in free form or in pharmaceutically acceptable salt form, in the manuf...
Gespeichert in:
| Hauptverfasser: | , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | GILBERT RICHARD ERNEST CHADBAN STEVEN JAMES COOPER MARK EMMANUEL NIKOLIC-PATERSON DAVID JOHN ATKINS ROBERT CHARLES KELLY DARREN JAMES HILL PRUDENCE ANN |
| description | The present invention relates to the use of PDGF receptor tyrosine kinase inhibitors, especially of N-phenyl-2-pyrim-idine-amine derivatives of formula (I), in which the symbols and substituents have the meaning as defined herein in free form or in pharmaceutically acceptable salt form, in the manufacture of a pharmaceutical composition for the treatment of diabetic nephropathy; to a method of treatment of warm-blooded animals, including humans, suffering from diabetic nephropathy; and to the use of a PDGF receptor tyrosine kinase inhibitor of the formula (I), wherein R1 is pyridyl bonded at a carbon atom, R2, R3, R5, R6 and R8 are each hydrogen, R4 is lower alkyl, R7 a radical of formula (II): -N(R9)-C(=X)-(Y)n-R10, wherein R9 hydrogen, X is oxo, n is 0 and R10 is 4-methyl-piperazinyl-methyl, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating glomerulonephritis, chronic pyelonephritis or IgA nephropathy. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_US2003186977A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>US2003186977A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_US2003186977A13</originalsourceid><addsrcrecordid>eNqNi7EKwjAURbM4iPoPD5yF1oLVUURx1w5OJU1vzENNQvKW_r0t-AFOZzjnzNWjyaBgKfZPSwkGUUIiGVLI7EEv9noM2DvueDSZ7KQdSBK0fOBlunvWHYQNeUSXQtTihqWaWf3OWP24UOvL-X66bhBDixy1gYe0zW1bFFW53x3q-lhW_1Vf9qY8HA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy</title><source>esp@cenet</source><creator>GILBERT RICHARD ERNEST ; CHADBAN STEVEN JAMES ; COOPER MARK EMMANUEL ; NIKOLIC-PATERSON DAVID JOHN ; ATKINS ROBERT CHARLES ; KELLY DARREN JAMES ; HILL PRUDENCE ANN</creator><creatorcontrib>GILBERT RICHARD ERNEST ; CHADBAN STEVEN JAMES ; COOPER MARK EMMANUEL ; NIKOLIC-PATERSON DAVID JOHN ; ATKINS ROBERT CHARLES ; KELLY DARREN JAMES ; HILL PRUDENCE ANN</creatorcontrib><description>The present invention relates to the use of PDGF receptor tyrosine kinase inhibitors, especially of N-phenyl-2-pyrim-idine-amine derivatives of formula (I), in which the symbols and substituents have the meaning as defined herein in free form or in pharmaceutically acceptable salt form, in the manufacture of a pharmaceutical composition for the treatment of diabetic nephropathy; to a method of treatment of warm-blooded animals, including humans, suffering from diabetic nephropathy; and to the use of a PDGF receptor tyrosine kinase inhibitor of the formula (I), wherein R1 is pyridyl bonded at a carbon atom, R2, R3, R5, R6 and R8 are each hydrogen, R4 is lower alkyl, R7 a radical of formula (II): -N(R9)-C(=X)-(Y)n-R10, wherein R9 hydrogen, X is oxo, n is 0 and R10 is 4-methyl-piperazinyl-methyl, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating glomerulonephritis, chronic pyelonephritis or IgA nephropathy.</description><edition>7</edition><language>eng</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2003</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20031002&DB=EPODOC&CC=US&NR=2003186977A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20031002&DB=EPODOC&CC=US&NR=2003186977A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>GILBERT RICHARD ERNEST</creatorcontrib><creatorcontrib>CHADBAN STEVEN JAMES</creatorcontrib><creatorcontrib>COOPER MARK EMMANUEL</creatorcontrib><creatorcontrib>NIKOLIC-PATERSON DAVID JOHN</creatorcontrib><creatorcontrib>ATKINS ROBERT CHARLES</creatorcontrib><creatorcontrib>KELLY DARREN JAMES</creatorcontrib><creatorcontrib>HILL PRUDENCE ANN</creatorcontrib><title>Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy</title><description>The present invention relates to the use of PDGF receptor tyrosine kinase inhibitors, especially of N-phenyl-2-pyrim-idine-amine derivatives of formula (I), in which the symbols and substituents have the meaning as defined herein in free form or in pharmaceutically acceptable salt form, in the manufacture of a pharmaceutical composition for the treatment of diabetic nephropathy; to a method of treatment of warm-blooded animals, including humans, suffering from diabetic nephropathy; and to the use of a PDGF receptor tyrosine kinase inhibitor of the formula (I), wherein R1 is pyridyl bonded at a carbon atom, R2, R3, R5, R6 and R8 are each hydrogen, R4 is lower alkyl, R7 a radical of formula (II): -N(R9)-C(=X)-(Y)n-R10, wherein R9 hydrogen, X is oxo, n is 0 and R10 is 4-methyl-piperazinyl-methyl, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating glomerulonephritis, chronic pyelonephritis or IgA nephropathy.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2003</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNi7EKwjAURbM4iPoPD5yF1oLVUURx1w5OJU1vzENNQvKW_r0t-AFOZzjnzNWjyaBgKfZPSwkGUUIiGVLI7EEv9noM2DvueDSZ7KQdSBK0fOBlunvWHYQNeUSXQtTihqWaWf3OWP24UOvL-X66bhBDixy1gYe0zW1bFFW53x3q-lhW_1Vf9qY8HA</recordid><startdate>20031002</startdate><enddate>20031002</enddate><creator>GILBERT RICHARD ERNEST</creator><creator>CHADBAN STEVEN JAMES</creator><creator>COOPER MARK EMMANUEL</creator><creator>NIKOLIC-PATERSON DAVID JOHN</creator><creator>ATKINS ROBERT CHARLES</creator><creator>KELLY DARREN JAMES</creator><creator>HILL PRUDENCE ANN</creator><scope>EVB</scope></search><sort><creationdate>20031002</creationdate><title>Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy</title><author>GILBERT RICHARD ERNEST ; CHADBAN STEVEN JAMES ; COOPER MARK EMMANUEL ; NIKOLIC-PATERSON DAVID JOHN ; ATKINS ROBERT CHARLES ; KELLY DARREN JAMES ; HILL PRUDENCE ANN</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_US2003186977A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2003</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>GILBERT RICHARD ERNEST</creatorcontrib><creatorcontrib>CHADBAN STEVEN JAMES</creatorcontrib><creatorcontrib>COOPER MARK EMMANUEL</creatorcontrib><creatorcontrib>NIKOLIC-PATERSON DAVID JOHN</creatorcontrib><creatorcontrib>ATKINS ROBERT CHARLES</creatorcontrib><creatorcontrib>KELLY DARREN JAMES</creatorcontrib><creatorcontrib>HILL PRUDENCE ANN</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>GILBERT RICHARD ERNEST</au><au>CHADBAN STEVEN JAMES</au><au>COOPER MARK EMMANUEL</au><au>NIKOLIC-PATERSON DAVID JOHN</au><au>ATKINS ROBERT CHARLES</au><au>KELLY DARREN JAMES</au><au>HILL PRUDENCE ANN</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy</title><date>2003-10-02</date><risdate>2003</risdate><abstract>The present invention relates to the use of PDGF receptor tyrosine kinase inhibitors, especially of N-phenyl-2-pyrim-idine-amine derivatives of formula (I), in which the symbols and substituents have the meaning as defined herein in free form or in pharmaceutically acceptable salt form, in the manufacture of a pharmaceutical composition for the treatment of diabetic nephropathy; to a method of treatment of warm-blooded animals, including humans, suffering from diabetic nephropathy; and to the use of a PDGF receptor tyrosine kinase inhibitor of the formula (I), wherein R1 is pyridyl bonded at a carbon atom, R2, R3, R5, R6 and R8 are each hydrogen, R4 is lower alkyl, R7 a radical of formula (II): -N(R9)-C(=X)-(Y)n-R10, wherein R9 hydrogen, X is oxo, n is 0 and R10 is 4-methyl-piperazinyl-methyl, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating glomerulonephritis, chronic pyelonephritis or IgA nephropathy.</abstract><edition>7</edition><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng |
| recordid | cdi_epo_espacenet_US2003186977A1 |
| source | esp@cenet |
| subjects | CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T07%3A28%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=GILBERT%20RICHARD%20ERNEST&rft.date=2003-10-02&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EUS2003186977A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |